№ 2 (187) 2024 р. С. 50–56

МЕТАБОЛІЧНИЙ СИНДРОМ, ДИСЛІПОПРОТЕЇНЕМІЇ І МЕЛАТОНІН

О. О. Сергієнко, В. Б. Сегін, М. Я. Камінська, В. О. Сергієнко

Львівський національний медичний університет імені Данила Галицького, Львів, Україна
Комунальне неприбуткове підприємство Львівської обласної ради «Львівська обласна клінічна лікарня», Львів, Україна

DOI 10.32782/2226-2008-2024-2-9

Метаболічний синдром (МС) – це сукупність факторів ризику серцево-судинних захворювань, зокрема ожиріння, дисліпопротеїнемій, хронічного запалення низької інтенсивності, оксидантного стресу, інсулінової резистентності. Отже, для успішного лікування МС необхідний потенційний допоміжний лікарський засіб, який володіє антагоністичними ефектами на тригерні фактори МС. Дефіцит вироблення мелатоніну (МЕЛ) або порушення експресії рецепторів нейрогормону пов’язані з ожирінням, артеріальною гіпертензією, цукровим діабетом 2-го типу. Зокрема, існує значущий взаємозв’язок між рівнями МЕЛ та інсуліну у пацієнтів з МС, а також між співвідношенням МЕЛ/інсулін та змінами ліпідного профілю крові. Особлива увага в огляді приділена опису особливостей механізмів дії МЕЛ на ліпідний обмін, а також аналізу доказів експериментальних і клінічних випробувань МЕЛ.

Ключові слова: метаболічний синдром, ожиріння, дисліпопротеїнемії, мелатонін.

ЛІТЕРАТУРА

  1. Cherkas A, Eckl P, Gueraud F et al. Helicobacter pylori in sedentary men is linked to higher heart rate, sympathetic activity, and insulin resistance but not inflammation or oxidative stress. Croat Med J. 2016; 57(2): 141–149. doi: 10.3325/ cmj.2016.57.141.
  2. Ziegler D, Porta M, Papanas N et al. The role of biofactors in diabetic microvascular complications. Curr Diabetes Rev. 2022; 18(4): e250821195830. doi: 10.2174/1871527320666210825112240.
  3. Serhiyenko VA, Serhiyenko LM, Sehin VB, Serhiyenko AA. Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview. Endocr Regul. 2022; 56(4): 284–294. doi: 10.2478/enr-2022-0031.
  4. Donohoe F, Wilkinson M, Baxter E, Brennan DJ. Mitogen-activated protein kinase (MAPK) and obesity-related cancer. Int J Mol Sci. 2020; 21(4): 1241. doi: 10.3390/ijms21041241.
  5. Moschonis G, Trakman GL. Overweight and obesity: the interplay of eating habits and physical activity. 2023; 15(13): 2896. doi: 10.3390/nu15132896.
  6. Abood SJ, Abdulsahib WK, Hussain SA, Ismail SH. Melatonin potentiates the therapeutic effects of metformin in women with metabolic syndrome. Sci Pharm. 2020; 88(2): 28. doi: 10.3390/scipharm88020028.
  7. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. Focus (Am Psychiatr Publ). 2018; 16(1): 113–118. doi: 10.1176/appi.focus.16101.
  8. Ahmad SB, Ali A, Bilal M et al. Melatonin and health: Insights of melatonin action, biological functions, and associated disorders. Cell Mol Neurobiol. 2023; 43(6): 2437–2458. doi: 10.1007/s10571-023-01324-w.
  9. Wang L, McFadden JW, Yang G et al. Effect of melatonin on visceral fat deposition, lipid metabolism and hepatic lipometabolic gene expression in male rats. J Anim Physiol Anim Nutr (Berl). 2021; 105: 787–796. doi: 10.1111/jpn.13497.
  10. Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022; 7: 265. doi: 10.1038/s41392-022-01125-5.
  11. Mi Y, Tan D, He Y, Zhou X, Zhou Q, Ji S. Melatonin modulates lipid metabolism in HepG2 cells cultured in high concentrations of oleic acid: AMPK pathway activation may play an important role. Cell Biochem Biophys. 2018; 76(4): 463–470. doi: 10.1007/s12013-018-0859-0.
  12. Karolczak K, Watala C. The mystery behind the pineal gland: melatonin affects the metabolism of cholesterol. Oxid Med Cell Longev. 2019; 2019: 4531865. doi: 10.1155/2019/4531865.
  13. Hong F, Pan S, Xu P et al. Melatonin orchestrates lipid homeostasis through the hepatointestinal circadian clock and microbiota during constant light exposure. 2020; 9(2): 489. doi: 10.3390/cells9020489.
  14. Li Y, Ma J, Yao K et al. Circadian rhythms and obesity: Timekeeping governs lipid metabolism. J Pineal Res. 2020; 69(3): e12682. doi: 10.1111/jpi.12682.
  15. Martín V, Sanchez-Sanchez AM, Herrera F et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013; 108(10): 2005–2012. doi: 10.1038/bjc.2013.188.
  16. Kaddah S, Khreich N, Kaddah F, Charcosset C, Greige-Gerges H. Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem Toxicol. 2018; 113: 40–48. doi: 10.1016/j.fct.2018.01.017.
  17. Čejková S, Králová-Lesná I, Poledne R. Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development. Cor Vasa. 2016; 58(4): e419–e425. doi: 10.1016/j.crvasa.2015.08.002.
  18. Cherkas A, Abrahamovych O, Golota S et al. The correlations of glycated hemoglobin and carbohydrate metabolism parameters with heart rate variability in apparently healthy sedentary young male subjects. Redox Biol. 2015; 5: 301–307. doi: 10.1016/j.redox.2015.05.007.
  19. Serhiyenko V, Serhiyenko A, Segin V, Serhiyenko L. Association of arterial stiffness, N-terminal pro-brain natriuretic peptide, insulin resistance, and left ventricular diastolic dysfunction with diabetic cardiac autonomic neuropathy. Vessel Plus. 2022; 6: 11. doi: 10.20517/2574-1209.2021.83.
  20. Choi Y, Attwood SJ, Hoopes MI, Drolle E, Karttunen M, Leonenko Z. Melatonin directly interacts with cholesterol and alleviates cholesterol effects in dipalmitoylphosphatidylcholine monolayers. Soft Matter. 2014; 10(1): 206–213. doi: 10.1039/C3SM52064A.
  21. Hevia D, González-Menéndez P, Quiros-González I et al. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res. 2015; 58(2): 234–250. doi: 10.1111/jpi.12210.
  22. Ou TH, Tung YT, Yang TH, Chien YW. Melatonin improves fatty liver syndrome by inhibiting the lipogenesis pathway in hamsters with high-fat diet-induced hyperlipidemia. 2019; 11(4): 748. doi: 10.3390/nu11040748.
  23. Liu W, Zhang Y, Chen Q et al. Melatonin alleviates glucose and lipid metabolism disorders in guinea pigs caused by different artificial light rhythms. J Diabetes Res. 2020; 2020: 4927403. doi: 10.1155/2020/4927403.
  24. Ku H, Kim Y, Kim AL, Lee G, Choi Y, Kim B. Protective effects of melatonin in high-fat diet-induced hepatic steatosis via decreased intestinal lipid absorption and hepatic cholesterol synthesis. Endocrinol Metab (Seoul). 2023; 38(5): 557–567. doi: 10.3803/EnM.2023.1672.
  25. Yang W, Tang K, Wang Y, Zhang Y, Zan L. Melatonin promotes triacylglycerol accumulation via MT2 receptor during differentiation in bovine intramuscular preadipocytes. Sci Rep. 2017; 7(1): 15080. doi: 10.1038/s41598-017-12780-y.
  26. de Souza CAP, Gallo CC, de Camargo LS et al. Melatonin multiple effects on brown adipose tissue molecular machinery. J Pineal Res. 2019; 66(2): e12549. doi: 10.1111/jpi.12549.
  27. Liu Z, Gan L, Luo D, Sun C. Melatonin promotes circadian rhythm-induced proliferation through Clock/histone deacetylase 3/c-Myc interaction in mouse adipose tissue. J Pineal Res. 2017; 62(4): e12383. doi: 10.1111/jpi.12383.
  28. Delpino FM, Figueiredo LM. Melatonin supplementation and anthropometric indicators of obesity: A systematic review and meta-analysis. 2021; 91–92: 111399. doi: 10.1016/j.nut.2021.111399.
  29. Li Z, Zheng M, Mo J et al. Single-cell RNA sequencing of preadipocytes reveals the cell fate heterogeneity induced by melatonin. J Pineal Res. 2021; 70(3): e12725. doi: 10.1111/jpi.12725.
  30. Biggio G, Biggio F, Talani G et al. Melatonin: from neurobiology to treatment. Brain Sci. 2021; 11(9): 1121. doi: 10.3390/ brainsci11091121.
  31. Santos-Ledo A, Luxán-Delgado B, Caballero B et al. Melatonin ameliorates autophagy impairment in a metabolic syndrome model. Antioxidants (Basel). 2021; 10(5): 796. doi: 10.3390/antiox10050796.
  32. Cardinali DP, Brown GM, Pandi-Perumal SR. Melatonin’s benefits and risks as a therapy for sleep disturbances in the elderly: current insights. Nat Sci Sleep. 2022; 14: 1843–1855. doi: 10.2147/NSS.S380465.
  33. Tung YT, Chiang PC, Chen YL, Chien YW. Effects of melatonin on lipid metabolism and circulating irisin in Sprague-Dawley rats with diet-induced obesity. 2020; 25(15): 3329. doi: 10.3390/molecules25153329.
  34. Guan Q, Wang Z, Cao J, Dong Y, Chen Y. Mechanisms of melatonin in obesity: A review. Int J Mol Sci. 2021; 23(1): 218. doi: 10.3390/ijms23010218.
  35. Adikwu E, Bokolo B. Melatonin and N-acetylcysteine as remedies for tramadol-induced hepatotoxicity in albino rats. Adv Pharm Bull. 2017; 7(3): 367–374. doi: 10.15171/apb.2017.044.
  36. Allagui MS, Hachani R, Saidi S et al. Pleiotropic protective roles of melatonin against aluminium-induced toxicity in rats. Gen Physiol Biophys. 2015; 34(4): 415–424. doi: 10.4149/gpb_2015028.
  37. Wang HR, Woo YS, Bahk WM. The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review. Int Clin Psychopharmacol. 2016; 31(6): 301–306. doi: 10.1097/YIC.0000000000000135.
  38. Ghaderi A, Banafshe HR, Mirhosseini N et al. The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment. Addict Biol. 2019; 24(4): 754–764. doi: 10.1111/ adb.12650.
  39. Uluişik D, Keskin E, Hatipoğlu D. A study on effect of melatonin in dyslipidemia caused by experimentally diabetes. TJSE. 2019; 21(1): 117–121. doi: 10.15314/tsed.541834.
  40. Al-Sarraf IAK, Kasabri V, Akour A, Naffa R. Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study. Horm Mol Biol Clin Investig. 2018; 35(2). Available from: /j/hmbci.2018.35.issue-2/ hmbci-2018-0016/hmbci-2018-0016.xml. doi: 10.1515/hmbci-2018-0016.
  41. Goyal A, Terry PD, Superak HM et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014; 6: 124. doi: 10.1186/1758-5996-6-124.
  42. Chojnacki C, Błońska A, Chojnacki J. The effects of melatonin on elevated liver enzymes during statin treatment. Biomed Res Int. 2017; 2017: 3204504. doi: 10.1155/2017/3204504.
  43. Mohammadi-Sartang M, Ghorbani M, Mazloom Z. Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2018; 37(6 Pt A): 1943–1954. doi: 10.1016/j. clnu.2017.11.003.
  44. Peneva VM, Terzieva DD, Mitkov MD. Role of melatonin in the onset of metabolic syndrome in women. Biomedicines. 2023; 11(6): 1580. doi: 10.3390/biomedicines11061580.
  45. Abood SJ, Abdulsahib WK, Hussain SA, Ismail SH. Melatonin potentiates the therapeutic effects of metformin in women with metabolic syndrome. Sci Pharm. 2020; 88(2): 28. doi: 10.3390/scipharm88020028.
  46. Sun H, Wang X, Chen J et al. Melatonin treatment improves insulin resistance and pigmentation in obese patients with acanthosis nigricans. Int J Endocrinol. 2018; 2018: 2304746. doi: 10.1155/2018/2304746.
  47. Boutin JA, Kennaway DJ, Jockers R. Melatonin: facts, extrapolations and clinical trials. 2023; 13(6): 943. doi: 10.3390/biom13060943.
  48. Loloei S, Sepidarkish M, Heydarian A et al. The effect of melatonin supplementation on lipid profile and anthropometric indices: A systematic review and meta-analysis of clinical trials. Diabetes Metab Syndr. 2019; 13(3): 1901–1910. doi: 10.1016/j.dsx.2019.04.043.
  49. Celinski K, Konturek PC, Slomka M et al. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease–14 months follow up. J Physiol Pharmacol. 2014; 65(1): 75–82. PMID: 24622832.
  50. Ozkalayci F, Kocabas U, Altun BU, Pandi-Perumal S, Altun A. Relationship between melatonin and cardiovascular disease. 2021; 13(1): e12935. doi: 10.7759/cureus.12935.
  51. Genario R, Cipolla-Neto J, Bueno AA, Santos HO. Melatonin supplementation in the management of obesity and obesity-associated disorders: a review of physiological mechanisms and clinical applications. Pharmacol Res. 2021; 163: 105254. doi: 10.1016/j.phrs.2020.105254.
Переглянути публікацію PDF